Drugs / bivalent Oral Polio Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05166031 | Dec 2020 → Apr 2021 | poliomyelitis | Fidec Corporation | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bivalent Oral Polio Vaccine | “bivalent Oral Polio Vaccine (bOPV)” NCT05166031 ↗ |
| Known as | bOPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05166031 ↗ |
| Modality | Vaccine | “bivalent Oral Polio Vaccine” NCT05166031 ↗ |
| Route | Oral | “bivalent Oral Polio Vaccine” NCT05166031 ↗ |